2022 American Transplant Congress

TOPIC: Clinical Science » Infection Disease » 28 - PTLD: All Topics

Clinical Outcomes of Solid Organ Transplant (SOT) Patients with Epstein-Barr Virus-Driven (EBV⁺) Post-Transplant Lymphoproliferative Disease (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study
V. Dharnidharka¹, D. Thirumalai², U. Jaeger³, W. Zhao², D. Dierickx⁴, P. Xun², P. Minga⁵, A. Sawas⁶, N. Sadetsky⁷, P. Chauvet⁸, E. Sundaram⁹, A. Barlev⁷, H. Zimmermann¹⁰, R. U. Trappe¹⁰
EBV+ PTLD Tumor MicroRNAs Detected in Circulating Extracellular Vesicles Are Decreased in Pediatric Transplant Recipients with EBV+ PTLD
A. Sen¹, J. Enriquez¹, M. Rao¹, M. Glass¹, Y. Balachandran¹, S. Syed¹, C. Twist¹, K. Weinberg¹, S. D. Boyd¹, D. Bernstein¹, A. Trickey¹, D. Gratzinger¹, B. Tan¹, M. G. Lapasaran¹, M. A. Robien², M. Brown³, B. Armstrong⁴, M. Sever⁴, D. Desai⁵, G. Mazariegos⁶, C. Chin⁷, T. Fishbein⁸, R. S. Venick⁹, A. Tekin¹⁰, H. Zimmermann¹¹, R. U. Trappe¹², C. O. Esquivel¹, O. M. Martinez¹, S. M. Krams¹
Incidence of Posttransplant Lymphoproliferative Disorder with Belatacept Therapy versus Calcineurin Inhibitor Therapy Alone: Data from One Academic Medical Center
K. Addonizio¹, G. Petrossian¹, A. Hsiao¹, L. Teixeira¹, N. Koizumi², R. James², S. Patel³, R. Plews¹, D. Conti¹, J. Ortiz¹
Post-Transplant Lymphoproliferative Disorder in Kidney and Simultaneous Pancreas and Kidney Transplant Recipients Predictors, and Patient and Allograft Outcomes
M. A. Mohamed¹, E. A. Yousif¹, V. Manchala², F. Aziz³, N. Garg⁴, S. Parajuli⁴, D. Mandelbrot⁵, B. Astor¹
Pre-Emptive Rituximab Use for Epstein-Barr Virus (EBV) Viremia in Cardiothoracic Solid Organ Transplant Recipients
B. Astorga, A. Loethen, L. Potter
PTLD Suspected by Visualization of Atypical Urinary Lymphocytes
J. Huidobro E¹, F. Anghileri², P. Troncoso³, A. Huete⁴, P. Downey¹
Risk of Post-Transplant Lymphoproliferative Disease After Anti-Thymocyte Globulin in Childhood Solid-Organ Transplant Recipients
A. M. McKay¹, C. Teoh¹, J. Vasilevska-Ristovka², J. Browne², T. Banh², A. Dipchand¹, V. Ng¹, M. Solomon¹, U. Allen¹, Y. Avitzur¹, R. Parekh³
Tabelecleucel (Tab-cel) for Solid Organ (SOT) or Allogeneic Hematopoietic Cell Transplant (HCT) Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease (EBV⁺ PTLD) After Failure Of Rituximab (R) ± Chemotherapy (CT) (ALLELE)
S. Prockop¹, A. Beitinjaneh², S. Choquet³, S. Dahiya⁴, R. Dinavahi⁵, R. Farah⁶, L. Gamelin⁵, A. Joshi⁵, A. Mehta⁵, P. Nayak⁵, R. Reshef⁷, G. Satyanarayana⁸, P. Stiff⁹, W. Ye⁵, K. M. Mahadeo¹⁰